verapamil modified release / Generic mfg. - LARVOL DELTA

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Florida | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: City of Hope Medical Center | Initiation date: Jan 2026 ➔ Dec 2026

Trial initiation date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: City of Hope Medical Center | Initiation date: Oct 2025 ➔ Jan 2026

Trial initiation date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Construction and in vitro/ in vivo evaluations of pulse sustained release of verapamil hydrochloride delivery system. (PubMed, Pak J Pharm Sci) - "The findings showed that a verapamil hydrochloride pulsatile release suspension prepared with custom-made porous cation exchange resin achieved controlled and sustained release, potentially improving adherence in cardiovascular therapy by better aligning with disease progression. It is also likely to reduce dosing frequency and plasma concentration fluctuations, offering significant clinical value in the personalized management of conditions such as hypertension and angina."

Journal • Preclinical • Cardiovascular • Hypertension

AN INTERESTING CASE OF SEVERE CALCIUM CHANNEL BLOCKER OVERDOSE (CHEST 2025) - "CASE PRESENTATION: A 23-year-old male with a history of hypertension and morbid obesity presented to the emergency department after an intentional overdose on verapamil extended-release... This case highlights the critical management strategies for a life-threatening verapamil overdose. Early intervention with resuscitation and antidote therapy, along with continuous monitoring and multi-disciplinary care, is essential for improving patient outcomes in such severe cases. This report underscores the need for prompt recognition and aggressive treatment in the management of CCB toxicity."

Clinical • Acute Kidney Injury • Acute Respiratory Distress Syndrome • Addiction (Opioid and Alcohol) • Cardiovascular • Genetic Disorders • Hypertension • Hypotension • Nephrology • Obesity • Renal Disease • Respiratory Diseases

Management of Acute Tinnitus With Migraine Medications (clinicaltrials.gov) - P4 | N=100 | Active, not recruiting | Sponsor: University of California, Irvine | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2026 ➔ Dec 2026 | Trial primary completion date: May 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Migraine • Otorhinolaryngology • Pain

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: University of Florida | Trial primary completion date: Jul 2028 ➔ Oct 2028

Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P1/2 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: University of Florida | Trial completion date: Apr 2030 ➔ Jul 2030 | Initiation date: Apr 2025 ➔ Jul 2025 | Trial primary completion date: Apr 2028 ➔ Jul 2028

Trial completion date • Trial initiation date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Management of Acute Tinnitus With Migraine Medications (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: University of California, Irvine | Initiation date: Mar 2025 ➔ Jun 2025

Trial initiation date • CNS Disorders • Migraine • Otorhinolaryngology • Pain

TEMPO II: Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Morten Steen Kvistholm Jensen | Trial completion date: Jun 2027 ➔ Dec 2027 | Trial primary completion date: Jun 2025 ➔ Apr 2027

Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Management of Acute Tinnitus with Migraine Medications (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: University of California, Irvine

New P4 trial • CNS Disorders • Migraine • Otorhinolaryngology • Pain

Ver-A-T1D: Verapamil SR in Adults With Type 1 Diabetes (clinicaltrials.gov) - P2 | N=138 | Active, not recruiting | Sponsor: Medical University of Graz | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

DON'T BE BRASH: A FATAL CASE OF VERAPAMIL OVERDOSE (CHEST 2024) - "CASE PRESENTATION: A 68-year-old female with a history of hypertension (on lisinopril and verapamil) and severe depression with persistent suicidal ideation presented to the emergency department after being found unresponsive at home...A thorough medication reconciliation revealed a missing verapamil SR 240 mg bottle despite a recent refill...Interventions are comprised by fluid resuscitation, IV glucagon, high-dose insulin infusion, bradycardia management (atropine, epinephrine infusion, ventricular pacing), and more advanced therapies, including IV lipid emulsion and extracorporeal membrane oxygenation (ECMO). Calcium channel overdose and BRASH syndrome both carry a high mortality rate. Early recognition and management are crucial to improve patient survival."

Clinical • Cardiovascular • CNS Disorders • Depression • Epilepsy • Gastrointestinal Disorder • Hypertension • Hypotension • Infectious Disease • Migraine • Nephrology • Pain • Pneumonia • Psychiatry • Renal Disease • Respiratory Diseases • Septic Shock • Suicidal Ideation

TEMPO II: Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Morten Steen Kvistholm Jensen | Trial completion date: Jun 2025 ➔ Jun 2027

Trial completion date • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: University of Florida

New P2 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Use of Intravenous Lipid Emulsion Therapy and Insulin in a Case of Tarka Intoxication. (PubMed, WMJ) - "ILE is an alternative treatment method for acute lipophilic drug intoxications, such as Tarka."

Journal • Cardiovascular • Diabetes • Hypotension • Metabolic Disorders

NAVIGATING THE STORM! UNRAVELING THE COMPLEXITIES OF CALCIUM CHANNEL BLOCKER TOXICITY (ACC 2024) - "Her medications included Verapamil 240 mg extended-release tablets once daily... Hyperinsulinemic Euglycemia Therapy, lipid emulsion therapy, and vasopressors are needed in severe CCB toxicities. Rescue anti-vasoplegic therapy with intravenous methylene blue needs to be considered on a case-to-case basis"

Acute Respiratory Distress Syndrome • Atrial Fibrillation • Cardiovascular • CNS Disorders • Hypertension • Hypoglycemia • Hypotension • Psychiatry • Pulmonary Disease • Respiratory Diseases • Schizophrenia

LEVERAGING MACHINE LEARNING TO ILLUMINATE PREDICTORS OF LONG-TERM MORTALITY: AN IN-DEPTH ANALYSIS OF HYPERTENSIVE PATIENTS WITH CAD (ACC 2024) - "We utilized machine learning methods (MLM) to analyze predictors of long-term mortality. We used data from the US cohort of the INternational VErapamil SR-Trandolapril Study (INVEST), a randomized controlled trial of hypertensive patients ≥50 years old with CAD evaluating a calcium antagonist vs β blocker strategy. In a machine learning model applied to a large population of older hypertensive patients with CAD, the top contributors to long-term outcomes were age, race, diabetes, and BP variability."

Clinical • Machine learning • Diabetes • Metabolic Disorders

The Use of Angiotensin II for Severe Vasodilatory Shock After Verapamil Poisoning (SCCM 2024) - "Description: A 14-year-old female with past medical history of depression presented after intentional ingestion of approximately 4080 mg of extended-release verapamil...She was given calcium gluconate, and epinephrine and norepinephrine infusions were initiated... Though well documented in the adult literature, the use of angiotensin II is not well defined in the pediatric literature. Further studies are needed to define the clinical role of angiotensin II infusions for refractory vasodilatory shock."

CNS Disorders • Critical care • Depression • Hypotension • Pediatrics • Psychiatry

Therapeutic Plasma Exchange for Refractory Verapamil Poisoning (SCCM 2024) - "Description: A 14-year-old female with past medical history of depression presented after intentional ingestion of approximately 4080 mg of extended-release verapamil...After cannulation with ECMO flows of 100 ml/kg/min, she continued to require high vasoactive support with epinephrine of 0.7 mcg/kg/min, norepinephrine of 0.7 mcg/kg/min, vasopressin of 0.06 units/min, insulin 10 units/kg/hr, and D12.5% at 80 cc/hr... There are limited case reports for the use of TPE in verapamil poisoning. Verapamil is a highly protein bound medication, and the use of TPE may be an important adjunctive therapy to enhance drug clearance."

Cardiovascular • CNS Disorders • Critical care • Depression • Hypotension • Pediatrics • Psychiatry

Ver-A-T1D: Verapamil SR in Adults With Type 1 Diabetes (clinicaltrials.gov) - P2 | N=138 | Recruiting | Sponsor: Medical University of Graz

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis. (PubMed, Clin Pharmacol Ther) - "An oral dosage of 360 mg sustained-release (SR) verapamil given every 12 hours concomitantly with rifampin achieved median verapamil exposures of 903.1 ng.h/ml (AUC 0-12h) in the 18 participants receiving this highest studied verapamil dose; these AUC findings are similar to those in persons receiving daily doses of 240 mg verapamil SR but not rifampin. Finally, rifampin exposures were 50% greater after verapamil administration, which may also be advantageous. Our findings suggest that a higher dosage of verapamil can be safely used as adjunctive treatment in rifampin-containing treatment regimens."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Ver-A-T1D: Verapamil SR in Adults With Type 1 Diabetes (clinicaltrials.gov) - P2 | N=138 | Recruiting | Sponsor: Medical University of Graz | Trial completion date: Feb 2024 ➔ Apr 2026 | Trial primary completion date: Feb 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Preparation of Sustained Release Formulation of Verapamil Hydrochloride Using Ion Exchange Resins. (PubMed, AAPS PharmSciTech) - "The results indicated that the rate-limiting step is the diffusion of the exchanging cations through the liquid film. The modified release formulation was prepared successfully and correlated very well with the USP monograph for verapamil hydrochloride extended release capsules."

Journal